
Optum Specialty Pharmacy is the specialty pharmacy service of Optum Rx, the pharmacy care business of Optum within UnitedHealth Group Incorporated (NYSE: UNH), headquartered in Minnetonka, Minnesota. The service, which operated under the BriovaRx name until its 2019 to 2020 rebrand, dispenses complex and high-cost medications through specialty pharmacies based in Irvine, California, supported by Optum's payer, care delivery, and data platforms. It is one of the three largest US specialty pharmacies by dispensing volume.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Optum Specialty Pharmacy | UnitedHealth Group | Brand division |
UnitedHealth Group built its specialty pharmacy capability through acquisition. The foundational deal came in 2015, when Optum acquired Catamaran Corporation for approximately $12.8 billion. Catamaran, a pharmacy benefit manager, brought a specialty pharmacy operation that Optum consolidated into its pharmacy care business.
In 2015, Optum unified its specialty pharmacy operations under the BriovaRx name, folding in related operations it had acquired including AxelaCare, a home infusion provider. BriovaRx handled specialty dispensing, infusion, and patient support through facilities including the Irvine, California hub and other national sites.
The rebrand to Optum Specialty Pharmacy began in October 2019 as part of Optum's broader effort to consolidate sub-brands under the Optum master identity. BriovaRx Infusion became Optum Infusion Pharmacy, and the transition ran through the end of 2020, after which the BriovaRx name was retired.
Under the Optum name, the service has expanded its limited-distribution drug access, gene and cell therapy support through Optum Frontier Therapies, and clinical programs organized by therapeutic area. It competes within the Big 3 of PBM-affiliated specialty pharmacies that collectively handle roughly two-thirds of US specialty dispensing.
UnitedHealth Group operates through two primary platforms that work together to deliver comprehensive healthcare solutions: UnitedHealthcare and Optum. This integrated business model enables the company to serve the entire healthcare continuum, from insurance coverage to direct healthcare delivery and technology services, creating synergies that enhance both quality and efficiency.
UnitedHealthcare represents the company's health insurance and benefits division, providing coverage to individuals, employers, and government-sponsored programs including Medicare and Medicaid. In 2025, UnitedHealthcare served 49.8 million consumers and achieved revenues of $344.9 billion, representing 16% growth year-over-year. The division operates through multiple business segments including individual and family plans, employer-sponsored coverage, Medicare Advantage plans, and Medicaid managed care programs.
UnitedHealthcare's success stems from its extensive provider networks, innovative benefit designs, and focus on value-based care models. The company has developed sophisticated approaches to care coordination, preventive health programs, and chronic disease management that improve health outcomes while managing costs effectively. UnitedHealthcare's market leadership position enables it to negotiate favorable terms with healthcare providers and develop innovative insurance products that meet evolving consumer needs.
Optum delivers comprehensive healthcare services and technology solutions through three main segments that support the entire healthcare ecosystem:
Optum Health provides direct patient care and health services, operating clinics, surgical centers, and home health services. The segment employs healthcare professionals including physicians, nurses, and care coordinators who deliver integrated care to patients across various settings. Optum Health focuses on value-based care models that align financial incentives with health outcomes, creating more efficient and effective healthcare delivery systems.
Optum Insight offers data analytics, consulting, and technology services to healthcare organizations, payers, and life sciences companies. The segment leverages UnitedHealth Group's vast healthcare data assets to provide insights that improve clinical outcomes, reduce costs, and enhance operational efficiency. Optum Insight's services include population health management, revenue cycle optimization, and healthcare technology implementation.
Optum Rx manages pharmacy benefits for millions of people, negotiating with pharmaceutical manufacturers and managing prescription drug programs. In 2025, Optum Rx achieved 15% revenue growth, demonstrating strong performance in the pharmacy benefits management market. The segment combines purchasing power with clinical expertise to optimize medication therapy, improve adherence, and manage drug costs effectively.
UnitedHealth Group's integrated business model creates significant competitive advantages. The company's ability to combine insurance coverage with direct healthcare delivery enables better care coordination, improved health outcomes, and more efficient resource utilization. This integration also provides valuable data insights that inform product development, care management programs, and operational improvements.
In 2025, UnitedHealth Group demonstrated exceptional financial performance with consolidated revenues of $447.6 billion, representing 12% growth year-over-year. The company's adjusted earnings from operations reached $21.7 billion, reflecting strong operational execution despite challenges including cyberattack-related costs and business restructuring charges.
In Q2 2026, UnitedHealth Group reported revenues of $112.0 billion and earnings from operations of $8.0 billion, with net margin of 4.9%. Cash flows from operations were $11.1 billion, or 1.9 times net income. UnitedHealthcare served 48.5 million consumers (down from 49.8 million in 2025) and reported Q2 2026 revenues of $86.0 billion with earnings of $3.9 billion. Optum supported over 120 million consumers and generated Q2 2026 revenues of $65.7 billion with earnings of $4.0 billion, representing 160 basis points of margin expansion year over year.
The company's financial metrics demonstrate operational efficiency and strong cash generation. UnitedHealth Group achieved cash flows from operations of $19.7 billion in 2025, representing 1.5 times net income. The company maintains a debt-to-capital ratio of 41.2% (as of June 30, 2026) and targets a long-term ratio of 40.0%, reflecting prudent financial management.
UnitedHealth Group employs approximately 440,000 people worldwide, making it one of the largest employers in the healthcare industry. The company's workforce includes healthcare professionals, technology specialists, data analysts, and business professionals who support the company's integrated healthcare delivery model.
Looking toward 2026, UnitedHealth Group initially established revenue guidance greater than $439.0 billion (a 2% decline reflecting divestitures and membership reduction) and adjusted earnings outlook greater than $17.75 per share. After strong Q2 2026 results, the company raised its full-year 2026 guidance to adjusted net earnings of $19.50 to $20.00 per share, with earnings from operations greater than $25.2 billion. The company expects operating earnings from UnitedHealthcare to exceed $12 billion, Optum Health to exceed $2.2 billion, Optum Insight to exceed $4.9 billion, and Optum Rx to exceed $6.25 billion. Cash flows from operations are expected to be approximately $24 billion, with share repurchases of at least $5 billion.
The service operates within the broader controversy facing UnitedHealth Group, including DOJ investigation into the company's business practices and criticism of PBM vertical integration. Independents argue that channeling patients to affiliated specialty pharmacies disadvantages community pharmacies; UnitedHealth defends the model on adherence and cost grounds. No specialty-pharmacy-specific regulatory finding against Optum Specialty Pharmacy has been publicly resolved as of late 2026.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Cvs Health | USA | 2014 | Mass market | United states | All Genders | |
| Cencora | USA | 1994 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by CVS Health Corporation
Specialty pharmacy service of CVS Health, providing mail-order and clinical support for complex, high-cost medications treating chronic and rare conditions.
Healthcare PharmaceuticalsOwned by Cencora Inc.
Independent specialty pharmacy of Cencora, acquired in 2003, providing high-cost therapies, reimbursement support, and clinical services for complex conditions.
Market Positioning: Optum Specialty Pharmacy competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by UnitedHealth Group, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
Band-Aid is privately owned, unlike Optum Specialty Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
Benadryl is privately owned, unlike Optum Specialty Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Optum Specialty Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Optum Specialty Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American brand of ibuprofen pain relief medication owned by Kenvue, the consumer health spinoff from Johnson & Johnson, which is being acquired by Kimberly-Clark in a $40 billion deal announced in November 2025.
Motrin is privately owned, unlike Optum Specialty Pharmacy which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Kenvue
American brand of over-the-counter first aid antibiotic ointment containing bacitracin, neomycin, and polymyxin B. Owned by Kenvue (NYSE: KVUE) since the August 2023 spin-off from Johnson & Johnson.
Neosporin is privately owned, unlike Optum Specialty Pharmacy which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Specialty pharmacy founded in 1996 in Memphis, serving patients with complex and rare conditions as the specialty pharmacy of Evernorth within The Cigna Group.